Stock Analysis: JNJ
Johnson & Johnson
JNJ · Healthcare · Pharmaceuticals
Johnson & Johnson is a global healthcare company that researches, develops, and manufactures a wide range of products in the pharmaceutical and medical technology fields. The company operates through two primary segments: Innovative Medicine and MedTech.
Fair Value Summary
Current Price
$270.47
Fair Value
$297.91
Margin of Safety
+9.2%
52-Week Range
$199.91 – $290.25
Scenario Price Targets
Bear Case
$138.20
Base Case
$311.73
Bull Case
$856.63
How We Built This Fair Value
Why “Hold”?
JNJ trades near its blended fair value of $297.91, based on DCF, P/E, and Graham models.
The fundamentals are supported by positive free cash flow, low leverage, 16% net margins.
This is a research output, not personalized investment advice.
Save this JNJ analysis to your inbox
Get this full report emailed to you so you can revisit it anytime, plus a weekly note with undervalued stock ideas. Free, no credit card.
We'll only email you about JNJ and your weekly brief. Unsubscribe anytime.
Your JNJ analysis is ready
Save this report or share it before you scroll on. The full breakdown is below.
How fragile is this fair value?
Nudge expected growth by 3 points and the discount rate by 1 point, and JNJ's DCF value moves between $197.66 and $541.01 (base $311.73). This range covers the DCF model only, not the blended fair value above.
Unlock the full sensitivity tablePro also adds the Investment Committee's five framework stress tests on this thesis.
Financial Health
Revenue
$99.3B
Net Income
$16.1B
Free Cash Flow
$20.6B
Gross Margin
67.8%
Operating Margin
26.6%
Net Margin
16.2%
ROE
20.0%
ROIC
21.6%
Debt/Equity
0.55
Current Ratio
1.02
Revenue Growth
5.9%
P/E Ratio
41.1
Forward P/E
24.3
PEG Ratio
3.43
Dividend Yield
1.97%
Beta
0.20
Top 3 Risk Factors
Dividend Sustainability
Payout ratio of 81% is high - dividend may be at risk if earnings decline.
JNJ's dividend sustainability was flagged as a risk.
Dividend Safety Scorer Quantifies whether the dividend survives a downturn: payout coverage, free-cash-flow backing, and balance-sheet strength, scored 0-100.
Stress-test the dividend Start Pro, risk-free for 30 daysKeep Reading
Value any stock with 5 models
Fair value, risks, earnings red flags, and an AI analyst. $70/year.
2027 Tax Strategy for Investors: The Complete Legal Tax-Reduction Playbook
Read article options tradingOptions Trading for Beginners: Calls, Puts, and the Greeks Explained
Read article behavioral financeThe Psychology of Money: 8 Mental Biases That Destroy Investment Returns
Read article options tradingOptions Basics: How to Use Derivatives to Protect Your Portfolio Without Gambling
Read articleKnow what a stock is worth before you buy it.
Five valuation models, an AI research analyst, and an all-account wealth dashboard. $70 a year — a fraction of one research subscription.
